ProCE Banner Activity

Phase III AGAIN (JCOG1404/WJOG8214L) Trial: First-line EGFR-TKI Monotherapy vs EGFR-TKI and Inserted Cisplatin/Pemetrexed in Advanced Nonsquamous, EGFR-Mutated NSCLC

Conference Coverage
Slideset

Insertion of 3 cycles of platinum-doublet CT after initial response to first-line EGFR-TKI therapy did not improve overall survival for patients with advanced nonsquamous, EGFR-mutated NSCLC.

Released: June 05, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Merck Sharp & Dohme Corp., and Novocure.

AstraZeneca

Daiichi Sankyo

Merck Sharp & Dohme Corp.

Novocure